Clinical Trials
3 trialsNCT04487106 2025-04-22
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02016729 2019-02-27
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
Kartos Therapeutics, Inc.
Phase 1 Completed
NCT00920140 2014-04-02
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
GlaxoSmithKline
Phase 2 Completed